JP2023549675A5 - - Google Patents

Info

Publication number
JP2023549675A5
JP2023549675A5 JP2023526000A JP2023526000A JP2023549675A5 JP 2023549675 A5 JP2023549675 A5 JP 2023549675A5 JP 2023526000 A JP2023526000 A JP 2023526000A JP 2023526000 A JP2023526000 A JP 2023526000A JP 2023549675 A5 JP2023549675 A5 JP 2023549675A5
Authority
JP
Japan
Prior art keywords
composition according
sars
composition
lipid
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023526000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/057825 external-priority patent/WO2022098701A1/en
Publication of JP2023549675A publication Critical patent/JP2023549675A/ja
Publication of JP2023549675A5 publication Critical patent/JP2023549675A5/ja
Pending legal-status Critical Current

Links

JP2023526000A 2020-11-03 2021-11-03 呼吸器疾患に関連する状態の治療および予防 Pending JP2023549675A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108980P 2020-11-03 2020-11-03
US63/108,980 2020-11-03
PCT/US2021/057825 WO2022098701A1 (en) 2020-11-03 2021-11-03 Treatment and prevention of conditions associated with respiratory diseases

Publications (2)

Publication Number Publication Date
JP2023549675A JP2023549675A (ja) 2023-11-29
JP2023549675A5 true JP2023549675A5 (cg-RX-API-DMAC10.html) 2024-11-12

Family

ID=81458208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023526000A Pending JP2023549675A (ja) 2020-11-03 2021-11-03 呼吸器疾患に関連する状態の治療および予防

Country Status (8)

Country Link
US (1) US20250195638A1 (cg-RX-API-DMAC10.html)
EP (1) EP4240329A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023549675A (cg-RX-API-DMAC10.html)
KR (1) KR20230104640A (cg-RX-API-DMAC10.html)
CN (2) CN116669708A (cg-RX-API-DMAC10.html)
AU (1) AU2021373711A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196661A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022098701A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116669708A (zh) * 2020-07-22 2023-08-29 休斯敦大学系统 呼吸系统疾病相关病症的治疗和预防

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471778A4 (en) * 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
CN106667914B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
CN106727331B (zh) * 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 免疫脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
KR101982710B1 (ko) * 2017-03-17 2019-05-28 주식회사 큐라티스 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물
TW202003032A (zh) * 2018-03-23 2020-01-16 美商科迪亞克生物科學公司 包含s t i n g 促效劑之胞外囊泡
CN111187354B (zh) * 2020-02-20 2020-11-27 北京新创生物工程有限公司 新型冠状病毒(SARS-CoV-2)IgM/IgG抗体检测试剂盒
CN111303254A (zh) * 2020-02-20 2020-06-19 北京新创生物工程有限公司 新型冠状病毒(SARS-CoV-2)抗原检测试剂盒
CN113456810A (zh) * 2020-03-30 2021-10-01 杭州星鳌生物科技有限公司 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用
CN116669708A (zh) * 2020-07-22 2023-08-29 休斯敦大学系统 呼吸系统疾病相关病症的治疗和预防

Similar Documents

Publication Publication Date Title
EP2184067B1 (en) Severe acute respiratory syndrome DNA vaccine compositions and methods of use
Weeratna et al. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
JP2023513720A5 (cg-RX-API-DMAC10.html)
JP5331340B2 (ja) インフルエンザウィルスワクチン組成物、及びその使用方法
US7504107B2 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
KR20090109122A (ko) 암의 치료제
EP2961846A1 (en) Crimean-congo haemorrhagic fever virus antigenic composition
CN117050986B (zh) 具有免疫刺激活性的CpG寡聚核苷酸及其用途
JP2023535405A5 (cg-RX-API-DMAC10.html)
KR101751376B1 (ko) 점막 백신
KR102190180B1 (ko) Dna 백신
JP2001524934A (ja) 遺伝子治療ウイルスベクターの投与に対して哺乳類罹患動物を寛容化する方法
CN116568309B (zh) 一种用于预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒
Verthelyi Adjuvant properties of CpG oligonucleotides in primates
EP4175666A1 (en) A dna plasmid sars-coronavirus-2/covid-19 vaccine
CN100509056C (zh) 包含作为佐剂的i型ifn的疫苗和涉及它们的方法
JP7370983B2 (ja) ヘンドラウイルス感染症及びニパウイルス感染症に対するワクチン
US20230321230A1 (en) Compositions and Methods for Adjuvanted Vaccines
RU2823677C2 (ru) Cpg амфифилы и их применения
Oberemok et al. Adjuvant oligonucleotide vaccine increases survival of transgenic mice [B6. Cg-Tg (K18-ACE2) 2]
US20230390384A1 (en) Recombinant covid-19 vaccine composition comprising lipopeptide and poly (i:c) adjuvant, and use thereof
HK40102335A (en) Vaccines against hendra and nipah virus infection
KR20250113423A (ko) 안정화된 백신
TW202203970A (zh) 靶向冠狀病毒的IgY免疫球蛋白、其製備方法、及其使用方法
Hamdy et al. Nanotechnology for cancer vaccine delivery